Amicus Therapeutics FOLD reported its Q1 earnings results on Wednesday, May 10, 2023 at 07:00 AM.
Here's what investors need to know about the announcement.
Earnings
Amicus Therapeutics missed estimated earnings by 20.0%, reporting an EPS of $-0.18 versus an estimate of $-0.15.
Revenue was up $7.55 million from the same period last year.
Past Earnings Performance
Last quarter the company missed on EPS by $0.06 which was followed by a 6.35% drop in the share price the next day.
Here's a look at Amicus Therapeutics's past performance:
| Quarter | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 |
|---|---|---|---|---|
| EPS Estimate | -0.13 | -0.19 | -0.22 | -0.25 |
| EPS Actual | -0.19 | -0.12 | -0.21 | -0.30 |
| Revenue Estimate | 86.29M | 84.22M | 85.89M | 77.13M |
| Revenue Actual | 88.10M | 81.69M | 80.73M | 78.72M |
To track all earnings releases for Amicus Therapeutics visit their earnings calendar here.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
